IVF

INVO Fertility, Inc. (IVF) - 10-K Summary

Business Context and Reporting Period

This Annual Report on Form 10-K covers the fiscal year ended December 31, 2024. INVO Fertility, Inc. (formerly NAYA Biosciences, Inc.) is a healthcare services company focused on the fertility marketplace. Its strategy involves operating fertility clinics (including the acquired Wisconsin Fertility Institute and two INVO Centers) and selling the INVOcell medical device. In October 2024, the company acquired NAYA Therapeutics, Inc. (NTI), a clinical-stage oncology company. However, in April 2025, the company announced a strategic decision to divest a majority interest in NTI to refocus exclusively on fertility, changing its name to INVO Fertility, Inc. and its ticker symbol to "IVF."

Key Financial Metrics

Note: The filing text does not provide explicit gross margin percentages, but Cost of Revenue was $3.66 million in 2024 versus $1.93 million in 2023.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 117% to $6.53 million, primarily driven by the full-year inclusion of the Wisconsin Fertility Institute (WFI) acquired in August 2023.
• Acquisition Activity: The company acquired NAYA Therapeutics in October 2024, adding significant intangible assets ($14.6 million in-process R&D) and goodwill ($17.7 million). Conversely, the company is now planning to divest NTI.
• Capital Structure: The company executed a 1-for-12 reverse stock split in March 2025 to regain Nasdaq compliance. In January 2025, it raised approximately $9.5 million in a public offering.
• Debt Obligations: The company has substantial indebtedness, including a 7.0% Senior Secured Convertible Debenture of approximately $3.9 million due in December 2025 and outstanding acquisition payments for WFI totaling $7.5 million (with the second installment currently in negotiation).

Guidance, Outlook, and Risks

Outlook and Strategy: Management intends to divest NAYA Therapeutics in Q2 2025 to focus solely on the fertility business. The company plans to grow the WFI clinic and pursue additional IVF clinic acquisitions. It expects to continue incurring significant operating losses as it expands.

Going Concern: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative working capital of approximately $16.6 million as of December 31, 2024. The company states it will need to raise additional funding to meet liquidity needs.

Key Risks:

• Liquidity: Dependence on debt and equity financing to fund operations and service debt.
• Debt Default: Risk of default on the WFI acquisition payments and the Senior Secured Convertible Debenture.
• Regulatory/Listing: Recent history of Nasdaq non-compliance regarding minimum bid price and timely filing (though compliance was regained in March/April 2025).
• Internal Controls: Material weaknesses in internal control over financial reporting were identified, including insufficient segregation of duties and lack of adequate accounting resources.

Investor Verification Checklist

• Divestiture Status: Verify the progress of the planned divestiture of NAYA Therapeutics and the retention of a minority stake.
• WFI Payment Restructuring: Confirm the outcome of negotiations regarding the $2.5 million second installment payment for the Wisconsin Fertility Institute acquisition.
• Capital Adequacy: Assess the sufficiency of the $9.5 million raised in January 2025 to cover the $7.5 million in WFI payments, debt obligations, and operating losses for the next 12 months.
• Nasdaq Compliance: Monitor the company's ability to maintain the minimum bid price and timely filing requirements following the recent reverse split and 10-K filing.
• Internal Controls: Review the remediation plan for the material weaknesses in internal controls over financial reporting.